IQVIA, Real World Solutions, Zaventem 1930, Belgium.
Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
J Comp Eff Res. 2021 Apr;10(6):469-480. doi: 10.2217/cer-2020-0284. Epub 2021 Feb 12.
The study assesses the cost-effectiveness of empagliflozin versus glimepiride in patients with Type 2 diabetes and uncontrolled by metformin alone in China, based on the EMPA-REG H2H-SU trial. A calibrated version of the IQVIA Core Diabetes Model was used. Cost of complications and utility were taken from literature. The Chinese healthcare system perspective and 5% discounting rates were applied. Empagliflozin+metformin provides additional quality-adjusted life-years (0.317) driven by a reduction in the number of cardiovascular and renal events, for an additional cost of $1382 (CNY9703) compared with glimepiride+metformin. Empagliflozin is cost-effective treatment versus glimepiride applying a threshold of $30,290 (CNY212,676).
本研究基于 EMPA-REG H2H-SU 试验，评估了恩格列净相对于格列美脲在二甲双胍单药控制不佳的中国 2 型糖尿病患者中的成本效益。使用了经过校准的 IQVIA Core Diabetes Model。并发症的成本和效用来自文献。采用中国医疗保健系统视角和 5%的贴现率。与格列美脲+二甲双胍相比，恩格列净+二甲双胍可通过减少心血管和肾脏事件来增加质量调整生命年（0.317），额外成本为 1382 美元（9703 元人民币）。如果采用 30290 美元（212676 元人民币）的阈值，恩格列净相对于格列美脲是具有成本效益的治疗方法。
